比较ixekizumab和阿达木单抗治疗中重度银屑病伴银屑病关节炎患者的甲银屑病：来自一项多中心、随机、开放性、评估者设盲研究（SPIRIT-H2H）的24周结果
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
关键信息
- 在患银屑病关节炎伴有银屑病的患者中，甲银屑病较为普遍，有多达80%至90%的银屑病患者在其生活中的某个时段内受其影响。
- 该SPIRIT-H2H研究（NCT03151551）的事后亚组分析比较了IL-17A拮抗剂ixekizumab和TNFα阻断剂阿达木单抗在活动性银屑病关节炎伴有中重度银屑病患者中治疗甲银屑病至第24周的疗效。
- 在该事后分析中， ixekizumab（80.0%）与阿达木单抗（52.5%）相比，其第24周指甲受累的完全缓解率明显更高，证实了ixekizumab治疗甲银屑病的已确定疗效。
- 这证实了ixekizumab治疗甲银屑病的已确定疗效。
Presenting Author
Saxon D. Smith, MBChB, MHL, PhD
Northern Clinical School, Sydney Medical School, The University of Sydney
Sydney, Australia
Dr Saxon D Smith is a Fellow of the Australasian College of Dermatologists. He graduated medicine from the University of Otago, Dunedin, New Zealand, and has a Master Degree in Health Law from the University of Sydney. He completed his Doctor of Philosophy (Medicine) at the University of Sydney.
Dr Smith is the principal dermatologist at The Dermatology and Skin Cancer Centre in Gosford and St Leonards, NSW, Australia. He has been a clinical supervisor for dermatology trainees, higher degree by research students, and University of Sydney Doctorate of Medicine (MD) research supervisor/tutor. He has performed research in a broad range of areas in medical and surgical dermatology including adult and paediatric atopic dermatitis, adult and paediatric psoriasis, hidradentitis suppurativa, as well as the surgical and non-surgical management of non-melanoma skin cancer and melanoma. He is also currently involved in multiple pharmaceutical trials from phase II to phase IV.
Dr Smith has been a key note speaker and invited speaker to national and international conferences. He has over 75 peer reviewed journal publications and over 100 published abstracts.
Author disclosures
Saxon D. Smith: Advisory Panel: Abbvie, Biogen, Eli Lilly and Company, Janssen-Cilag, Johnson and Johnson Consumer Products Company, Novartis, Pfizer, Sanofi Genzyme; Research Support: Abbvie, BMS, Eli Lilly and Company, Novartis, Sanofi Genzyme, UCB, Regeneron; Speaker’s Bureau: Abbvie, Eli Lilly and Company, Leo, Novartis; Honoraria: Energizer Holdings, Inc.
